End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
36,150 KRW | +0.42% |
|
-3.60% | -18.67% |
06-19 | IMBiologics Signs $964 Million Licensing Deal for Autoimmune Treatments | MT |
04-04 | Protium Science Co.,Ltd. announced that it has received KRW 2 billion in funding from HK inno.N Corporation | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company benefits from high valuations in earnings multiples.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.67% | 742M | - | ||
+5.38% | 71.83B | A | ||
+23.57% | 9.56B | A- | ||
+30.09% | 4.85B | B- | ||
-21.31% | 4.48B | A- | ||
+24.78% | 3.9B | - | ||
+11.03% | 2.01B | - | - | |
-1.35% | 1.99B | B | ||
-36.28% | 1.89B | C- | ||
-43.19% | 1.77B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A195940 Stock
- Ratings HK inno.N Corporation